WILLIAM MCKEE
CIK 1237262 · Chief Financial Officer · last filed 2026-06-16
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$20.6K
Companies
8
Total Filings
48
Lifetime Open-Market Net
-$763.1K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Assertio Holdings, Inc. (ASRT) Delisted | Director | 0 | $23.50 | $0 | -$220.9K | 13 | 2026-06-16 |
| Rein Therapeutics, Inc. (ALRN) Delisted | Director | — | $2.11 | — | $0 | 4 | 2022-06-17 |
| CCCC | Chief Financial Officer | 5,263 | $3.92 | $20.6K | $100.0K | 1 | 2020-10-06 |
| AGILE THERAPEUTICS INC (AGRX) Delisted | Director | 9 | $1.51 | $14 | $0 | 5 | 2019-06-07 |
| Assertio Therapeutics, Inc (DEPO) Delisted | Director | — | — | — | $0 | 3 | 2018-05-10 |
| Dare Bioscience, Inc. (CERU) Delisted | Director | 342 | — | — | $0 | 4 | 2017-01-05 |
| AUXILIUM PHARMACEUTICALS INC (AUXL) Delisted | Director | 0 | — | — | -$642.2K | 9 | 2015-01-30 |
| BARR PHARMACEUTICALS INC (BRL) Delisted | EVP, CFO | 8,977 | — | — | $0 | 7 | 2008-12-19 |
Recent Filings · Page 3 of 5
48 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-06-08 | AGILE THERAPEUTICS INC (AGRX) Delisted | Mixed | +17,949 | $0 | EDGAR |
| 2018-05-10 | Assertio Therapeutics, Inc (DEPO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-08-16 | Assertio Therapeutics, Inc (DEPO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-06-09 | AGILE THERAPEUTICS INC (AGRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-03-30 | Assertio Therapeutics, Inc (DEPO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-01-05 | Dare Bioscience, Inc. (CERU) Delisted | Grant (A) | +1,948 | $1.5K | EDGAR |
| 2016-10-20 | Dare Bioscience, Inc. (CERU) Delisted | Grant (A) | +1,470 | $1.5K | EDGAR |
| 2016-06-24 | Dare Bioscience, Inc. (CERU) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-06-09 | AGILE THERAPEUTICS INC (AGRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-06-30 | Dare Bioscience, Inc. (CERU) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.